Jounce Therapeutics, Inc. Common Stock (JNCE)

JNCE was delisted on the 3rd of May, 2023.

• Market cap: $99M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

Employees: 141